Our research is focussed on the epidemiology of osteoporosis, defining optimal treatment pathways and identifying novel genetic pathways that influence osteoporosis risk.

We have shown the much higher than recognised prevalence of this problem and its association with ill-health, health care costs and premature death.  We have also shown that specific treatment can reduce the risk of premature death.

Our Dubbo Osteoporosis Epidemiology Study over nearly 25 years has provided major insights into the osteoporosis problem and remains the longest running study of osteoporosis in men and women world-wide.

We continue to focus on ways of improving care and identifying novel pathways as targets for new treatments.